Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

1.980 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80
Open 1.980
Bid (Size) 1.880 (5)
Ask (Size) 1.970 (2)
Prev. Close 1.980
Today's Range 1.980 - 1.980
52wk Range 0.7130 - 2.450
Shares Outstanding 36,382,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
From Quince Therapeutics, Inc.
Via Business Wire

Performance

YTD
+5.3%
+5.3%
1 Month
+23.7%
+23.7%
3 Month
+17.9%
+17.9%
6 Month
+98.0%
+98.0%
1 Year
+156.1%
+156.1%

More News

Read More
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
From Quince Therapeutics, Inc.
Via Business Wire
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
From Quince Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Quince Therapeutics to Present at Citizens Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Quince Therapeutics, Inc. - Common Stock publicly traded?
Yes, Quince Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Quince Therapeutics, Inc. - Common Stock trade on?
Quince Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Quince Therapeutics, Inc. - Common Stock?
The ticker symbol for Quince Therapeutics, Inc. - Common Stock is QNCX on the Nasdaq Stock Market
What is the current price of Quince Therapeutics, Inc. - Common Stock?
The current price of Quince Therapeutics, Inc. - Common Stock is 1.980
When was Quince Therapeutics, Inc. - Common Stock last traded?
The last trade of Quince Therapeutics, Inc. - Common Stock was at 10/15/25 04:00 PM ET
What is the market capitalization of Quince Therapeutics, Inc. - Common Stock?
The market capitalization of Quince Therapeutics, Inc. - Common Stock is 72.04M
How many shares of Quince Therapeutics, Inc. - Common Stock are outstanding?
Quince Therapeutics, Inc. - Common Stock has 72M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.